Monitoring of proteinuria in phase I studies in healthy male subjects

被引：0
|
作者：
G. Lemm
J. Küppers
R. Frey
W. Wingender
J. Kuhlmann
机构：
[1] Bayer AG,
[2] Pharma Research Centre,undefined
[3] Institute of Clinical Pharmacology,undefined
[4] Department Biochemical Pharmacology,undefined
[5] D-42096 Wuppertal,undefined
[6] Germany Tel.: +49 202 36 41 26; Fax: +49 202 36 46 32 e-mail: GEORG.LEMM.GL@bayer-ag.de,undefined
来源：
European Journal of Clinical Pharmacology | 1998年 / 54卷
关键词：
Key words Drug development; Nephrotoxicity; Pro- teinuria; Albuminuria; α1-Microglobulin; N-Acetyl-β-d-glucosaminidase;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: The quantitative measurement of urinary marker proteins may improve the sensitivity of monitoring renal function in healthy male subjects in phase I studies. Little is known about the variability of physiological proteinuria in young, healthy male subjects. Thus, the biological and analytical variability of three marker proteins, i.e. albumin, α1-microglobulin and N-acetyl-β-d-glucosaminidase (NAG), were investigated in this population.
引用
收藏
页码：287 / 294
页数：7
相关论文
共 4 条
1